Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5322 ARTÍCULOS , VIENDO DEL 1936 AL 1950

NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson's Disease

Han QQ, Le W.

Neurosci Bull. 2023 May;39(5):832-844. doi: 10.1007/s12264-023-01023-y. Epub 2023 Feb 9.

The function of Golgi apparatus in LRRK2-associated Parkinson's disease

Wei Y, Awan MUN, Bai L, Bai J.

Front Mol Neurosci. 2023 Feb 21;16:1097633. doi: 10.3389/fnmol.2023.1097633. eCollection 2023.

Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies

Moradi Vastegani S, Nasrolahi A, Ghaderi S, Belali R, Rashno M, Farzaneh M, Khoshnam SE.

Neurochem Res. 2023 Aug;48(8):2285-2308. doi: 10.1007/s11064-023-03904-0. Epub 2023 Mar 21.

Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson's disease

Zhuo Y, Li X, He Z, Lu M.

Stem Cell Res Ther. 2023 Apr 12;14(1):80. doi: 10.1186/s13287-023-03280-0.

Subjective cognitive decline in patients with Parkinson's disease: an updated review

Huang J, Yuan X, Chen L, Hu B, Jiang L, Shi T, Wang H, Huang W.

Front Aging Neurosci. 2023 May 26;15:1117068. doi: 10.3389/fnagi.2023.1117068. eCollection 2023.

[Research Progress of microRNA-7/124/155 in Parkinson's Disease]

Chen T, Chen H, Yan WH, Zhu MY.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Jun;45(3):484-492. doi: 10.3881/j.issn.1000-503X.15244.

Neuroinflammation and Mitochondrial Dysfunction in Parkinson's Disease: Connecting Neuroimaging with Pathophysiology

Pizarro-Galleguillos BM, Kunert L, Brüggemann N, Prasuhn J.

Antioxidants (Basel). 2023 Jul 12;12(7):1411. doi: 10.3390/antiox12071411.

Exploring the interplay between metabolomics and genetics in Parkinson's disease: Insights from ongoing research and future avenues

Santos-Rebouças CB, Cordovil Cotrin J, Dos Santos Junior GC.

Mech Ageing Dev. 2023 Dec;216:111875. doi: 10.1016/j.mad.2023.111875. Epub 2023 Sep 23.

Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases

Talbot NC, Luther PM, Spillers NJ, Ragland AR, Kidder EJ, Kelkar RA, Varrassi G, Ahmadzadeh S, Shekoohi S, Kaye AD.

Cureus. 2023 Dec 22;15(12):e50948. doi: 10.7759/cureus.50948. eCollection 2023 Dec.

Oral and intestinal dysbiosis in Parkinson's disease

Berthouzoz E, Lazarevic V, Zekeridou A, Castro M, Debove I, Aybek S, Schrenzel J, Burkhard PR, Fleury V.

Rev Neurol (Paris). 2023 Nov;179(9):937-946. doi: 10.1016/j.neurol.2022.12.010. Epub 2023 Mar 16.

Structural and functional changes in the retina in Parkinson's disease

Alves JN, Westner BU, Højlund A, Weil RS, Dalal SS.

J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):448-456. doi: 10.1136/jnnp-2022-329342. Epub 2023 Feb 17.

Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies

Ahmad MH, Rizvi MA, Ali M, Mondal AC.

Ageing Res Rev. 2023 Mar;85:101840. doi: 10.1016/j.arr.2022.101840. Epub 2023 Jan 2.

Serotonin 5-HT(1A) receptors and their interactions with adenosine A(2A) receptors in Parkinson's disease and dyskinesia

Pinna A, Parekh P, Morelli M.

Neuropharmacology. 2023 Mar 15;226:109411. doi: 10.1016/j.neuropharm.2023.109411. Epub 2023 Jan 4.

Recent Advances in the Treatment of Genetic Forms of Parkinson's Disease: Hype or Hope?

Cavallieri F, Cury RG, Guimarães T, Fioravanti V, Grisanti S, Rossi J, Monfrini E, Zedde M, Di Fonzo A, Valzania F, Moro E.

Cells. 2023 Feb 27;12(5):764. doi: 10.3390/cells12050764.

Proposal for a Biologic Staging System of Parkinson's Disease

Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T.

J Parkinsons Dis. 2023;13(3):297-309. doi: 10.3233/JPD-225111.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias